SRR33532828
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.450
- KRAS_SIGNALING_DN+0.370
- SPERMATOGENESIS+0.370
- OXIDATIVE_PHOSPHORYLATION+0.210
- MYC_TARGETS_V2+0.190
- XENOBIOTIC_METABOLISM+0.160
- FATTY_ACID_METABOLISM+0.140
- BILE_ACID_METABOLISM+0.110
- MTORC1_SIGNALING+0.080
- PEROXISOME+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- NOTCH_SIGNALING-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- UV_RESPONSE_DN-0.550
- INTERFERON_GAMMA_RESPONSE-0.530
- WNT_BETA_CATENIN_SIGNALING-0.500
- TNFA_SIGNALING_VIA_NFKB-0.490
- ALLOGRAFT_REJECTION-0.460
- TGF_BETA_SIGNALING-0.460
- MITOTIC_SPINDLE-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.901 |
| 2 | ERR2278863 | — | — | 0.897 |
| 3 | SRR934734 | — | — | 0.891 |
| 4 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.880 |
| 5 | SRR23303740 | — | — | 0.880 |
| 6 | SRR1387199 | GTEX | — | 0.874 |
| 7 | ERR2208968 | — | — | 0.874 |
| 8 | SRR12202427 | — | — | 0.865 |
| 9 | SRR25617918 | — | B | 0.859 |
| 10 | SRR1340907 | GTEX | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |